Evidence map›Paper›PMID 42212534›Full record

ReviewBioscience reports2026

Synaptic vesicle architecture modulates α-synuclein conformation and pathogenic transitions in Parkinson's disease.

Priyatosh Ranjan

Abstract readReview
In one paragraph

Review in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Priyatosh RanjanSchool of Sciences, Department of Biotechnology, Woxsen University, Hyderabad 502345, Telangana, India.ORCID 0000-0001-7575-8359

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

α-Synuclein (α-Syn) is a presynaptic protein implicated in the regulation of synaptic vesicle (SV) organization, soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex assembly, and neurotransmitter release through reversible interactions with curved lipid membranes. Increasing evidence indicates that α-Syn functions as a curvature-sensitive membrane adaptor whose N-terminal amphipathic helices selectively recognize the nanoscale architecture of SVs, thereby promoting vesicle tethering, clustering, and membrane fusion dynamics essential for synaptic transmission. Recent structural and biophysical studies demonstrate that SVs act as catalytic platforms in which membrane curvature, lipid packing defects, molecular crowding, and local physicochemical conditions determine whether α-Syn remains membrane-bound or transitions into pathogenic assemblies. Post-translational modifications, including phosphorylation, nitration, acetylation, and ubiquitination, dynamically regulate α-Syn conformation, membrane engagement, proteostatic turnover, aggregation propensity, and intracellular localization by modulating its structural plasticity and interactions with synaptic membranes. These modifications can alter electrostatic interactions, destabilize amphipathic helices, and shift α-Syn from functional membrane-associated states toward soluble oligomeric and amyloidogenic species. Aging further exacerbates these transitions through alterations in SV lipid composition, membrane fluidity, oxidative membrane damage, impaired proteostasis, and defective vesicle trafficking, thereby destabilizing α-Syn-membrane interactions. The present review discusses how membrane remodeling, vesicle lipid composition, post-translational modifications, protein conformational dynamics, and aging collectively regulate α-Syn phase behavior, membrane binding, and pathological aggregation at the presynaptic terminal. Integrating structural biology, lipidomics, proteomics, and live-cell imaging approaches will identify mechanistic transitions linking physiological membrane engagement to neurodegenerative synucleinopathies and reveal therapeutic opportunities for preventing synaptic dysfunction, toxic condensate formation, and neurodegeneration in Parkinson's disease and related disorders associated with pathological α-Syn aggregation.

Indexed as

alpha-SynucleinParkinson DiseaseSynaptic VesiclesAnimalsHumansProtein ConformationProtein Processing, Post-TranslationalSynaptic Transmissionalpha-Synucleinamyloidintrinsically disordered proteinsrandom coil-helix transitionSNARE complex assemblysynaptic vesiclesynucleinopathies

Identifiers

PMID42212534
PMCPMC13270162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.